Cryoport, Inc. (CYRX) Q1 2025 Earnings Call Transcript
- Cryoport, Inc. (NASDAQ:CYRX ) Q1 2025 Results Conference Call May 7, 2025 5:00 PM ET Company Participants Jerrell Shelton - CEO Robert Stefanovich - CFO Mark Sawicki - Chief Scientific Officer Thomas Heinzen - VP IR and Corporate Development Todd Fromer - IR, KCSA Strategic Communications Conference Call Participants Kyle Crews - UBS Richard Baldry - ROTH Capital David Larsen - BTIG Subbu Nambi - Guggenheim Securities Matt Stanton - Jefferies Anna Snopkowski - KeyBanc Operator Good afternoon, and welcome to Cryoport's First Quarter 2025 Earnings Call. All participants will start in a listen-only mode.
- 05/07/2025
|
CryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue Estimates
- CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.43 per share a year ago.
- 05/07/2025
|
Cryoport Reports First Quarter 2025 Financial Results
- Commercial Cell & Gene therapy revenue of $7.2 million, up 33% year over year Q1 2025 revenue from continuing operations of $41.0 million, up 10% year over year Supporting 711 global clinical trials as of March 31, 2025 Strategic partnership with DHL; CRYOPDP divestiture expected to close Q2/Q3 2025 NASHVILLE, Tenn. , May 7, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (Cryoport), a global provider of temperature-controlled supply chain solutions for the life sciences sector, today announced financial results for the first quarter (Q1) ended March 31, 2025.
- 05/07/2025
|
CryoPort, Inc. (CYRX) Expected to Beat Earnings Estimates: Should You Buy?
- CryoPort (CYRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/30/2025
|
Cryoport to Report First Quarter 2025 Financial Results on May 7, 2025
- NASHVILLE, Tenn. , April 24, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global provider of supply chain solutions for the life sciences sector, today announced that the Company will report financial results for the first quarter ended March 31, 2025 on Wednesday, May 7, 2025 after U.S. markets close.
- 04/24/2025
|
Cryoport, Inc. (CYRX) Strategic Agreement and Transaction with DHL Group Call (Transcript)
- Cryoport, Inc. (NASDAQ:CYRX ) Strategic Agreement and Transaction with DHL Group Call March 31, 2025 8:30 AM ET Company Participants Todd Fromer - Investor Relations, KCSA Strategic Communications Jerrell Shelton - Chief Executive Officer Tom Heinzen - Vice President, Corporate Development & Investor Relations Robert Stefanovich - Chief Financial Officer Mark Sawicki - Chief Scientific Officer Conference Call Participants Puneet Souda - Leerink Partners Subbu Nambi - Guggenheim Paul Knight - KeyBanc Tejas Savant - Morgan Stanley David Larsen - BTIG David Saxon - Needham Operator Good morning, and welcome to Cryoport's Investor Conference Call. All participants will start in a listen-only mode.
- 03/31/2025
|
DHL Group acquires CRYOPDP from Cryoport to strengthen "DHL Health Logistics"
- DHL to acquire 100% of CRYOPDP, a leading specialty courier providing logistics services for clinical trials, biopharma, and cell & gene therapies. This acquisition enhances DHL's capabilities in specialty pharma logistics and supports Group's 2030 strategy to become a leader in life science and healthcare logistics.
- 03/31/2025
|
Cryoport to Host Investor Call to Discuss Recent Strategic Agreement and Transformative Transaction Today, March 31, 2025, at 8:30 a.m. ET
- NASHVILLE, Tenn. , March 31, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences sector, today announced that the Company will host an investor call today, Monday, March 31, 2025, at 8:30 a.m.
- 03/31/2025
|
Cryoport's MVE Biological Solutions Expands High-Efficiency Cryogenic Freezer Series With Answer to Evolving Needs of Fertility Clinics, Biorepositories and Clinical Laboratories
- NASHVILLE, Tenn. , March 12, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or "the Company"), a global leader in supply chain solutions for the life sciences, today announced the launch of MVE Biological Solutions' ("MVE") High-Efficiency 800 C, the latest addition to its next-generation High-Efficiency ("HE") Series of cryogenic freezers.
- 03/12/2025
|
Cryoport, Inc. (CYRX) Q4 2024 Earnings Call Transcript
- Start Time: 17:00 January 1, 0000 5:41 PM ET Cryoport, Inc. (NASDAQ:CYRX ) Q4 2024 Earnings Conference Call March 04, 2025, 17:00 PM ET Company Participants Jerrell Shelton - CEO Robert Stefanovich - CFO Mark Sawicki - Chief Scientific Officer Thomas Heinzen - VP IR and Corporate Development Todd Fromer - IR, KCSA Strategic Communications Conference Call Participants Anna Snopkowski - KeyBanc Capital Markets Puneet Souda - Leerink Partners David Saxon - Needham Subbu Nambi - Guggenheim David Larson - BTIG Richard Baldry - Roth Capital Kyle Crews - UBS Matt Stanton - Jefferies Operator Good afternoon, and welcome to Cryoport's Fourth Quarter and Full Year 2024 Earnings Conference Call. All participants will start in a listen-only mode.
- 03/04/2025
|
CryoPort, Inc. (CYRX) Reports Q4 Loss, Tops Revenue Estimates
- CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.51 per share a year ago.
- 03/04/2025
|
Cryoport Reports Fourth Quarter and Full Year 2024 Financial Results
- FY 2024 revenue of $228.4 million, in-line with company guidance Commercial Cell & Gene Therapy revenue rose to $26 million in FY 2024, up 20% year-over-year Supporting a record total of 701 global clinical trials as of December 31, 2024 NASHVILLE, Tenn. , March 4, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (Cryoport), a global leader in supply chain solutions for the life sciences industry, today announced financial results for the fourth quarter (Q4) and year ended (FY) December 31, 2024.
- 03/04/2025
|
Cryoport to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025
- NASHVILLE, Tenn. , Feb. 18, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2024 on Tuesday, March 4, 2025 after U.S. markets close.
- 02/18/2025
|
New Strong Buy Stocks for January 29th
- MC, LFST, EAT, CYRX and HCP have been added to the Zacks Rank #1 (Strong Buy) List on January 29, 2024.
- 01/29/2025
|
Cryoport Unveils State-of-the-Art Cryogenic Shipping System for Transporting Lifesaving Biologics and Temperature-Sensitive Therapies
- New High-Volume Shipping System, Improving Patient Accessibility, Will Be Showcased by Cryoport Systems at Phacilitate's Advanced Therapies Week in Dallas NASHVILLE, Tenn. , Jan. 21, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or "the Company"), a global leader in supply chain solutions for the life sciences, today unveiled its Cryoport Express® Cryogenic HV3 Shipping System ("HV3"), the Company's newest product innovation in Cryoport's comprehensive portfolio of global end-to-end temperature-controlled supply chain offerings.
- 01/21/2025
|
Moffitt Cancer Center and Cryoport Announce Strategic Collaboration
- Cryoport's CRYOGENE will provide Moffitt with state-of-the-art biorepository services TAMPA, Fla. and NASHVILLE, Tenn.
- 01/14/2025
|
Cryoport's MVE Biological Solutions Registers All Manufacturing Facilities with the U.S. Food and Drug Administration ("FDA")
- All Three MVE Biological Solutions' Manufacturing Facilities Are Registered With the FDA and All Applicable MVE Products Are Now Listed NASHVILLE, Tenn. , Jan. 6, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX), a global leader in supply chain solutions for the life sciences industry, today announced that MVE Biological Solutions ("MVE"), a Cryoport company and the leading global manufacturer of high-quality cryogenic freezers and dewars, has officially registered all three of its manufacturing facilities (located in Ball Ground, Georgia; New Prague, Minnesota; and Chengdu, China) with the U.S. Food and Drug Administration ("FDA").
- 01/06/2025
|
Cryoport Remains A Disappointing Prospect
- Cryoport operates in the promising life sciences sector but continues to suffer from poor fundamentals and significant cash flow challenges. Despite slight revenue growth in Q3 2024, the company remains unprofitable and has seen a drastic share price decline since my initial 'sell' rating. Recent financial improvements are minimal, with net losses narrowing and cash flow turning slightly positive, but the overall outlook remains bleak.
- 11/24/2024
|
Cryoport Expands IntegriCell™ Cryopreservation Services Solution with Opening of New Center of Excellence in Europe
- Facility Dedicated to Cryopreservation of Leukapheresis Starting Materials to Support Clinical and Commercial Cell-Based Therapy Programs NASHVILLE, Tenn. , Nov. 12, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences industry, today announced the opening of its newest IntegriCell™ facility in Villers-le-Bouillet, Liege, Belgium.
- 11/12/2024
|
Cryoport, Inc. (CYRX) Q3 2024 Earnings Call Transcript
- Cryoport, Inc. (NASDAQ:CYRX ) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Todd Fromer - Investor Relations, KCSA Strategic Communications Jerrell Shelton - Chief Executive Officer Robert Stefanovich - Chief Financial Officer Mark Sawicki - Chief Scientific Officer Thomas Heinzen - VP Investor Relations and Corporate Development Conference Call Participants Paul Knight - KeyBanc David Larsen - BTIG Puneet Souda - Leerink Partners Operator Good afternoon and welcome to the Cryoport Second Quarter 2024 Earnings Call. All participants will start in a listen-only mode.
- 11/09/2024
|
CryoPort, Inc. (CYRX) Reports Q3 Loss, Misses Revenue Estimates
- CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.31 per share a year ago.
- 11/07/2024
|
Cryoport Reports Third Quarter 2024 Financial Results
- Q3 2024 Life Sciences Services revenue up 9% year-over-year, including BioStorage/BioServices revenue up 12% year-over-year Supported a record total of 691 global clinical trials as of September 30, 2024 Company reaffirmed full year 2024 revenue guidance of $225 to $235 million NASHVILLE, Tenn. , Nov. 7, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (Cryoport), a global leader in supply chain solutions for the life sciences industry, today announced financial results for its third quarter (Q3) and first nine months (9M) of 2024.
- 11/07/2024
|
CryoPort, Inc. (CYRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- CryoPort (CYRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 10/31/2024
|
Cryoport to Report Third Quarter 2024 Financial Results on November 7, 2024
- NASHVILLE, Tenn. , Oct. 29, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the third quarter ended September 30, 2024 on Thursday, November 7, 2024 after U.S. markets close.
- 10/29/2024
|
Cryoport and Gulf Coast Regional Blood Center Launch Strategic Alliance to Enhance Cellular Therapy Services
- Partnership Coincides with the Grand Opening of Cryoport's State-Of-The-Art IntegriCell ™ Houston Facility NASHVILLE, Tenn. and HOUSTON , Oct. 22, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for the life sciences industry, and Gulf Coast Regional Blood Center ("GCRBC"), a non-profit community blood center serving more than 26 counties throughout the state of Texas, today announced a strategic alliance to enhance the availability of high-quality, manufacture-ready cryopreserved allogeneic leukopaks for cellular therapy research, development, and treatment.
- 10/22/2024
|
TMRW Life Sciences and Cryoport Systems Form Strategic Partnership to Elevate Standards for Frozen Egg, Embryo, and Sperm Offsite Storage and Biologistics
- Two ISO-Certified Industry Leaders Collaborate to Provide Fertility Clinics with Complete, Trusted Solutions for Secure IVF Specimen Management and Transport NASHVILLE, Tenn. and NEW YORK , Oct. 21, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for the life sciences industry, and TMRW Life Sciences ("TMRW"), a fertility technology company offering the highest standard of care in offsite storage for frozen eggs, embryos and sperm in the U.S. with the only FDA-cleared automated specimen management and storage platform, today announced a strategic partnership to provide fertility clinics with complete solutions for secure specimen management and transport.
- 10/21/2024
|
VGXI Selects Cryoport for Biostorage, Bioservices and Supply Chain Solutions to Advance Next-Generation Therapies
- Partnership Will Enhance Support for Biopharmaceutical Companies in Developing Cell and Gene Therapies and mRNA-Based Treatments NASHVILLE, Tenn. and CONROE, Texas , Oct. 15, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for the life sciences, and VGXI, Inc., (VXGI) a subsidiary of GeneOne Life Science Inc. ("GeneOne" KOSPI: 011000) today announced a strategic partnership to support biopharmaceutical companies in developing cell and gene therapies and mRNA-based treatments.
- 10/15/2024
|
Cryoport Launches its IntegriCell™ Cryopreservation Solution with Opening of New Facility at its Houston Campus
- The IntegriCell Platform Will Deliver High-Quality Cryopreservation Services for Cell-Based Therapies NASHVILLE, Tenn. , Oct. 7, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or "the Company"), a global leader in supply chain solutions for the life sciences, today announced the launch of its IntegriCell™ cryopreservation services solution provided by Cryoport Systems with the opening of its new facility located at Cryoport's integrated supply chain campus in Houston, Texas.
- 10/07/2024
|
SK pharmteco and Cryoport Partner for Cell and Gene Therapy Logistics and BioServices
- NASHVILLE, Tenn. and RANCHO CORDOVA, Calif.
- 09/25/2024
|
The Schall Law Firm Is Inquiring Into Possible Securities Fraud By Cryoport Inc And Shareholders Are Encouraged To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / August 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/22/2024
|
The Schall Law Firm Is Looking Into Cryoport Inc For Possible Securities Law Violations And Encourages Shareholders To Help
- LOS ANGELES, CA / ACCESSWIRE / August 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/20/2024
|
The Schall Law Firm Is Inquiring Into Potential Securities Law Violations By Cryoport Inc And Asks Investors To Help
- LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/18/2024
|
The Schall Law Firm Begins Investigation Into Cryoport Inc And Asks Shareholders To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / August 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/16/2024
|
The Schall Law Firm Opens Investigation Into Cryoport Inc And Encourages Shareholders To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/15/2024
|
The Schall Law Firm Initiates Investigation Into Claims Against Cryoport Inc And Urges Shareholders To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / August 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/14/2024
|
The Schall Law Firm Initiates Probe Into Allegations Against Cryoport Inc And Motivates Its Shareholders To Contact
- LOS ANGELES, CA / ACCESSWIRE / August 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/13/2024
|
The Schall Law Firm Begins Investigation Into Claims Against Cryoport Inc And Encourages Its Shareholders To Reach Out
- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/12/2024
|
The Schall Law Firm Initiates Investigation Into Claims Against Cryoport Inc And Urges Its Shareholders To Contact
- LOS ANGELES, CA / ACCESSWIRE / August 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/09/2024
|
The Schall Law Firm Begins Probe Into Allegations Against Cryoport Inc And Encourages Its Shareholders To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / August 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/08/2024
|
The Schall Law Firm Initiates Investigation Into Claims Against Cryoport Inc And Urges Its Shareholders To Get In Touch
- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/07/2024
|
Airbnb Reports Weak Earnings, Joins Cryoport, Tripadvisor, Lyft And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
- U.S. stock futures were higher this morning, with the Dow futures gaining around 300 points on Wednesday.
- 08/07/2024
|
Cryoport, Inc. (CYRX) Q2 2024 Earnings Call Transcript
- Cryoport, Inc. (NASDAQ:CYRX ) Q2 2024 Results Conference Call August 6, 2024 5:00 PM ET Company Participants Todd Fromer - Investor Relations-KCSA Strategic Communications Jerrell Shelton - Chief Executive Officer Mark Sawicki - Chief Scientific Officer Robert Stefanovich - Chief Financial Officer Conference Call Participants Paul Knight - KeyBanc David Larsen - BTIG Philip Song - Leerink Partners Matt Stanton - Jefferies Yuan Zhi - B. Riley David Saxon - Needham Operator [Abrupt Start] Cryoport Second Quarter 2024 Earnings Call.
- 08/06/2024
|
CryoPort, Inc. (CYRX) Reports Q2 Loss, Lags Revenue Estimates
- CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.42 per share a year ago.
- 08/06/2024
|
The Schall Law Firm Begins Investigation Into Claims Against Cryoport Inc And Encourages Its Shareholders To Contact
- LOS ANGELES, CA / ACCESSWIRE / August 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/06/2024
|
Cryoport Reports Second Quarter 2024 Financial Results
- Revenue improved sequentially across all businesses Commercial Cell & Gene Therapy revenue increased 51% year-over-year and 20% sequentially A record total of 684 global clinical trials supported as of June 30, 2024 Cost reduction initiatives anticipated to result in approximately $22 million of annualized cost savings and drive Cryoport towards its goal of profitable growth, as well as a return to positive Adjusted EBITDA in 2025 Company provides updated 2024 full-year revenue guidance of $225 to $235 million NASHVILLE, Tenn. , Aug. 6, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (Cryoport), a global leader in supply chain solutions for the life sciences, today announced financial results for its second quarter (Q2) and first half (H1) of 2024.
- 08/06/2024
|
Cryoport Announces $200 Million Repurchase Program and the Repurchase of $160 Million of Convertible Senior Notes
- $200 million repurchase program authorized to repurchase common stock and/or convertible notes Repurchasing approximately $160 million of 0.75% Senior Notes due in 2026 at an 11.5% discount to par value Principal balance reduced to approximately $186.2 million NASHVILLE, Tenn. , Aug. 6, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences, today announced that the Company's Board of Directors had authorized a repurchase program to purchase up to $200 million of the Company's common stock and/or convertible senior notes (the "2024 Repurchase Program").
- 08/06/2024
|
Cryoport Incorporated Stockholders Are Encouraged By The Schall Law Firm To Make Contact During The Initiation Of An Allegations Investigation
- LOS ANGELES, CA / ACCESSWIRE / July 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/30/2024
|
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Cryoport, Inc. (CYRX)
- NEW YORK, NY / ACCESSWIRE / July 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cryoport, Inc. ("Cryoport") (NASDAQ:CYRX) concerning possible violations of federal securities laws. On May 7, 2024, Cryoport announced "disappointing" first quarter earnings for fiscal 2024.
- 07/29/2024
|
Cryoport Incorporated Stockholders Are Encouraged By The Schall Law Firm To Make Contact During The Initiation Of An Allegations Investigation
- LOS ANGELES, CA / ACCESSWIRE / July 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/29/2024
|
Levi & Korsinsky Reminds Cryoport Investors of the Ongoing Investigation into Potential Violations of Securities Laws - CYRX
- NEW YORK, NY / ACCESSWIRE / July 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cryoport, Inc. ("Cryoport") (NASDAQ:CYRX) concerning possible violations of federal securities laws. On May 7, 2024, Cryoport announced "disappointing" first quarter earnings for fiscal 2024.
- 07/29/2024
|
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Cryoport, Inc. (CYRX)
- NEW YORK, NY / ACCESSWIRE / July 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cryoport, Inc. ("Cryoport") (NASDAQ:CYRX) concerning possible violations of federal securities laws. On May 7, 2024, Cryoport announced "disappointing" first quarter earnings for fiscal 2024.
- 07/26/2024
|
Cryoport Incorporated Stockholders Are Invited By The Schall Law Firm To Reach Out Amidst The Initiation Of An Allegations Investigation
- LOS ANGELES, CA / ACCESSWIRE / July 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/26/2024
|
ATTENTION Cryoport, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
- NEW YORK, NY / ACCESSWIRE / July 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cryoport, Inc. ("Cryoport") (NASDAQ:CYRX) concerning possible violations of federal securities laws. On May 7, 2024, Cryoport announced "disappointing" first quarter earnings for fiscal 2024.
- 07/25/2024
|
Did Cryoport, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate- CYRX
- NEW YORK, NY / ACCESSWIRE / July 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cryoport, Inc. ("Cryoport") (NASDAQ:CYRX) concerning possible violations of federal securities laws. On May 7, 2024, Cryoport announced "disappointing" first quarter earnings for fiscal 2024.
- 07/25/2024
|
Cryoport Incorporated Stockholders Are Invited By The Schall Law Firm To Reach Out Amidst The Initiation Of An Allegations Investigation
- LOS ANGELES, CA / ACCESSWIRE / July 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/24/2024
|
Levi & Korsinsky Reminds Shareholders of an Investigation into Cryoport, Inc. (CYRX) Regarding Potential Securities Fraud Allegations
- NEW YORK, NY / ACCESSWIRE / July 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cryoport, Inc. ("Cryoport") (NASDAQ:CYRX) concerning possible violations of federal securities laws. On May 7, 2024, Cryoport announced "disappointing" first quarter earnings for fiscal 2024.
- 07/23/2024
|
Cryoport Incorporated Stockholders Are Invited By The Schall Law Firm To Reach Out Amidst The Initiation Of An Allegations Investigation
- LOS ANGELES, CA / ACCESSWIRE / July 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/23/2024
|
Cryoport to Report Second Quarter 2024 Financial Results on August 6, 2024
- NASHVILLE, Tenn. , July 23, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences, today announced that the Company will report financial results for the second quarter ended June 30, 2024 on Tuesday, August 6, 2024 after U.S. markets close.
- 07/23/2024
|
Levi & Korsinsky Reminds Shareholders of an Investigation into Cryoport, Inc. (CYRX) Regarding Potential Securities Fraud Allegations
- NEW YORK, NY / ACCESSWIRE / July 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cryoport, Inc. ("Cryoport") (NASDAQ:CYRX) concerning possible violations of federal securities laws. On May 7, 2024, Cryoport announced "disappointing" first quarter earnings for fiscal 2024.
- 07/22/2024
|
Cryoport Incorporated Stockholders Are Invited By The Schall Law Firm To Reach Out Amidst The Initiation Of An Allegations Investigation
- LOS ANGELES, CA / ACCESSWIRE / July 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/22/2024
|
Cryoport Incorporated Stockholders Are Invited By The Schall Law Firm To Reach Out Amidst Initiation Of An Allegations Investigation
- LOS ANGELES, CA / ACCESSWIRE / July 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/19/2024
|
Stockholders Of Cryoport Incorporated Are Encouraged To Connect As The Schall Law Firm Begins An Investigation Into Allegations
- LOS ANGELES, CA / ACCESSWIRE / July 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/18/2024
|
Cryoport Inc Shareholders Are Invited To Contact As The Schall Law Firm Initiates A Probe Into Claims
- LOS ANGELES, CA / ACCESSWIRE / July 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/17/2024
|
Cryoport Inc Shareholders Are Called To Reach Out As The Schall Law Firm Begins An Inquiry Into Allegations
- LOS ANGELES, CA / ACCESSWIRE / July 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/16/2024
|
Shareholders Of Cryoport Inc Are Invited To Contact As The Schall Law Firm Initiates An Investigation Into Claims
- LOS ANGELES, CA / ACCESSWIRE / July 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/15/2024
|
Cryoport Inc Shareholders Are Encouraged To Reach Out As The Schall Law Firm Begins A Probe Into Allegations
- LOS ANGELES, CA / ACCESSWIRE / July 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/13/2024
|
Cryoport Inc Shareholders Are Urged To Contact As The Schall Law Firm Initiates An Investigation Into Claims
- LOS ANGELES, CA / ACCESSWIRE / July 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/12/2024
|
CryoPort (CYRX) Moves 26.7% Higher: Will This Strength Last?
- CryoPort (CYRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 07/12/2024
|
As The Schall Law Firm Starts An Investigation Into Allegations, Shareholders Of Cryoport Inc Are Encouraged To Contact
- LOS ANGELES, CA / ACCESSWIRE / July 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/11/2024
|
Shareholders Of Cryoport Inc Are Urged To Reach Out As The Schall Law Firm Begins A Probe Into Claims
- LOS ANGELES, CA / ACCESSWIRE / July 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/10/2024
|
Cryoport Inc Shareholders Are Encouraged To Contact As The Schall Law Firm Initiates An Investigation Into Allegations
- LOS ANGELES, CA / ACCESSWIRE / July 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/09/2024
|
CryoPort (CYRX) Loses -43.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- The heavy selling pressure might have exhausted for CryoPort (CYRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- 07/09/2024
|
The Schall Law Firm Begins Investigation Into Claims Against Cryoport Inc And Encourages Its Shareholders To Contact
- LOS ANGELES, CA / ACCESSWIRE / July 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/08/2024
|
Cryoport Inc Is Under Investigation By The Schall Law Firm And Shareholders Are Encouraged To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / July 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/07/2024
|
The Schall Law Firm Initiates Investigation Into Cryoport Inc And Calls On Its Shareholders To Connect
- LOS ANGELES, CA / ACCESSWIRE / July 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/06/2024
|
As The Schall Law Firm Begins Investigating Claims Against Cryoport Inc, It Encourages Its Shareholders To Contact
- LOS ANGELES, CA / ACCESSWIRE / July 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/05/2024
|
As The Schall Law Firm Starts Probing Allegations Against Cryoport Inc, Its Shareholders Are Urged To Get In Touch
- LOS ANGELES, CA / ACCESSWIRE / July 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/03/2024
|
Cryoport Inc Shareholders Are Encouraged To Connect As The Schall Law Firm Begins An Examination Of Allegations Against It
- LOS ANGELES, CA / ACCESSWIRE / July 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/02/2024
|
Shareholders Of Cryoport Inc Are Urged To Get In Touch As The Schall Law Firm Is Embarking On A Review Of Claims Against It
- LOS ANGELES, CA / ACCESSWIRE / July 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/01/2024
|
Shareholders Of Cryoport Inc Are Called To Communicate As The Schall Law Firm Is Launching An Inquiry Into Charges Against It
- LOS ANGELES, CA / ACCESSWIRE / June 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/30/2024
|
Shareholders Of Cryoport Inc Are Invited To Connect As The Schall Law Firm Is Scrutinizing Accusations Against It
- LOS ANGELES, CA / ACCESSWIRE / June 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/29/2024
|
Cryoport Inc Shareholders Are Encouraged To Establish Communication As The Schall Law Firm Is Examining Allegations Against It
- LOS ANGELES, CA / ACCESSWIRE / June 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/28/2024
|
Shareholders Of Cryoport Inc Are Encouraged To Reach Out As The Schall Law Firm Is Probing Allegations Against It
- LOS ANGELES, CA / ACCESSWIRE / June 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/27/2024
|
Shareholders Of Cryoport Inc Are Urged To Initiate Contact As The Schall Law Firm Is Investigating Claims Against It
- LOS ANGELES, CA / ACCESSWIRE / June 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/26/2024
|
Shareholders Of Cryoport Inc Are Urged To Initiate Contact As The Schall Law Firm Is Investigating Claims Against It
- LOS ANGELES, CA / ACCESSWIRE / June 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/25/2024
|
Cryoport Inc Shareholders Are Encouraged To Establish Communication As The Schall Law Firm Is Examining Allegations Against It
- LOS ANGELES, CA / ACCESSWIRE / June 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/24/2024
|
The Schall Law Firm Is Examining Allegations Against Cryoport Inc And Encourages Its Shareholders To Establish Communication
- LOS ANGELES, CA / ACCESSWIRE / June 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/23/2024
|
The Schall Law Firm Is Investigating Claims Against Cryoport Inc And Urges Its Shareholders To Make Contact
- LOS ANGELES, CA / ACCESSWIRE / June 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/22/2024
|
The Schall Law Firm Is Examining Allegations Against Cryoport Inc And Encourages Its Shareholders To Establish Communication
- LOS ANGELES, CA / ACCESSWIRE / June 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/21/2024
|
The Schall Law Firm Is Investigating Claims Against Cryoport Inc And Urges Its Shareholders To Make Contact
- LOS ANGELES, CA / ACCESSWIRE / June 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/20/2024
|
Cryoport and Minaris Regenerative Medicine Form Strategic Partnership to Support Advancement of Cell and Gene Therapies
- Partnership Will Provide Cell and Gene Therapy Industry with Fully Integrated Logistics and Manufacturing Services for Regenerative Medicine Products NASHVILLE, Tenn. and YOKOHAMA, Japan , June 20, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for the life sciences, and Minaris Regenerative Medicine Co., Ltd.
- 06/20/2024
|
The Schall Law Firm Is Probing Allegations Against Cryoport Inc And Encourages Its Investors To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / June 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/19/2024
|
The Schall Law Firm Is Investigating Claims Against Cryoport Inc And Urges Its Investors To Connect
- LOS ANGELES, CA / ACCESSWIRE / June 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/18/2024
|
Allegations Against Cryoport Inc (CYRX) Are Being Probed By The Schall Law Firm And Its Investors Are Encouraged To Establish Contact
- LOS ANGELES, CA / ACCESSWIRE / June 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/17/2024
|
The Schall Law Firm Has Started An Investigation Into Allegations Against Cryoport, Inc. (CYRX) And Urges Its Investors To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / June 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/11/2024
|
The Schall Law Firm has initiated a probe into claims against Cryoport, Inc. (CYRX) and encourages its investors to make contact
- LOS ANGELES, CA / ACCESSWIRE / June 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/09/2024
|
The Schall Law Firm has begun an investigation into allegations against Cryoport, Inc. (CYRX) and is inviting its investors to reach out
- LOS ANGELES, CA / ACCESSWIRE / June 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/08/2024
|
The Schall Law Firm has initiated a probe into claims against Cryoport, Inc. (CYRX) and encourages its investors to make contact
- LOS ANGELES, CA / ACCESSWIRE / June 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/07/2024
|
The Schall Law Firm Begins Investigation Into Allegations Against Cryoport, Inc. (CYRX) And Urges Its Investors To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / June 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/06/2024
|
The Schall Law Firm Initiates Probe Into Claims Against Cryoport, Inc. (CYRX) And Encourages Investors To Make Contact
- LOS ANGELES, CA / ACCESSWIRE / June 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/05/2024
|
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors to Contact the Firm
- LOS ANGELES , June 5, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ: CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/05/2024
|
The Schall Law Firm Commences Investigation into Allegations Against Cryoport, Inc. and Urges Investors to Reach Out
- LOS ANGELES, CA / ACCESSWIRE / June 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/04/2024
|
CYRX IMPORTANT INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / June 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/03/2024
|
IMPORTANT INVESTIGATION UPDATE: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / June 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/02/2024
|
IMPORTANT INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / June 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/01/2024
|
IMPORTANT INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/31/2024
|
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/30/2024
|
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/19/2024
|
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/18/2024
|
IMPORTANT SHAREHOLDER INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/17/2024
|
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/16/2024
|
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/15/2024
|
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/14/2024
|
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/13/2024
|
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/10/2024
|
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/09/2024
|
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/08/2024
|
Cryoport, Inc. (CYRX) Q1 2024 Earnings Call Transcript
- Cryoport, Inc. (NASDAQ:CYRX ) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants Todd Fromer – Investor Relations-KCSA Strategic Communications Jerrell Shelton – Chief Executive Officer Mark Sawicki – Chief Scientific Officer Robert Stefanovich – Chief Financial Officer Thomas Heinzen – Vice President-Corporate Development and Investor Relations Conference Call Participants Matt Stanton – Jefferies Philip Song – Leerink Partners Lucas Baranowski – UBS David Larsen – BTIG Paul Knight – KeyBanc Yuan Zhi – B. Riley David Saxon – Needham Operator Good afternoon and welcome to Cryoport Fourth Quarter and Full Year 2023 Earnings Conference Call.
- 05/07/2024
|
Cryoport Reports First Quarter 2024 Financial Results
- Q1 2024 revenue of $54.6 million 9% year-over-year increase in Commercial Cell & Gene Therapy revenue 9% year-over-year increase in BioStorage/BioServices revenue A total of 675 global clinical trials supported as of March 31, 2024 $242 - $252 million full year 2024 revenue guidance reiterated NASHVILLE, Tenn. , May 7, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (Cryoport), a global leader in supply chain solutions for the life sciences, today announced financial results for the three months ended March 31 (Q1), 2024.
- 05/07/2024
|
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/07/2024
|
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/06/2024
|
Cryoport to Report First Quarter 2024 Financial Results on May 7, 2024
- NASHVILLE, Tenn. , April 30, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX), a global leader in supply chain solutions for cell & gene therapies, today announced that the Company will report financial results for the first quarter ended March 31, 2024 on Tuesday, May 7, 2024 after U.S. markets close.
- 04/30/2024
|
Earnings Preview: CryoPort, Inc. (CYRX) Q1 Earnings Expected to Decline
- CryoPort (CYRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/25/2024
|
Cryoport, Inc. (CYRX) Q4 2023 Earnings Call Transcript
- Cryoport, Inc. (CYRX) Q4 2023 Earnings Call Transcript
- 03/12/2024
|
CryoPort, Inc. (CYRX) Reports Q4 Loss, Misses Revenue Estimates
- CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.24 per share a year ago.
- 03/12/2024
|
Cryoport Reports Fourth Quarter and Full Year 2023 Financial Results
- FY 2023 revenue of $233.3 million, in-line with guidance Year-over-year, Commercial Cell & Gene Therapy revenue rose 33%; BioStorage/BioServices revenue increased 45% Global clinical trials supported reached a record 675 NASHVILLE, Tenn., March 12, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for cell & gene therapies, today announced financial results for the fourth quarter (Q4) and year (FY) ended December 31, 2023.
- 03/12/2024
|
Cryoport to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
- NASHVILLE, Tenn. , Feb. 27, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX), a global leader in supply chain solutions for cell & gene therapies, today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2023 on Tuesday, March 12, 2024 after U.S. markets close.
- 02/27/2024
|
Analysts Estimate CryoPort, Inc. (CYRX) to Report a Decline in Earnings: What to Look Out for
- CryoPort, Inc. (CYRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/15/2024
|
Should You Buy CryoPort, Inc. (CYRX) After Golden Cross?
- After reaching an important support level, CryoPort, Inc. (CYRX) could be a good stock pick from a technical perspective. CYRX recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
- 02/13/2024
|
Cryoport and NIPPON EXPRESS HOLDINGS Form Global Strategic Partnership for Temperature-Controlled Supply Chain Services
- Companies Will Partner to Provide Complete Supply Chain Solutions for the Life Science and Biopharmaceutical Industries NASHVILLE, Tenn. , Nov. 27, 2023 /PRNewswire/ -- Cryoport Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative products and services to the fast-growing cell and gene therapy industry enabling the future of medicine for a new era of life sciences, and NIPPON EXPRESS HOLDINGS, INC.
- 11/27/2023
|
Cryoport's CRYOPDP Expands U.S. Footprint with Acquisition of Bluebird Express
- CRYOPDP's Acquisition of Bluebird Express Adds Further Domestic and International Transportation Services Strengthening CRYOPDP's U.S. Logistics Operations NASHVILLE, Tenn. , Nov. 16, 2023 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative products and services to the fast-growing cell and gene therapy industry enabling the future of medicine for a new era of life sciences, today announced the expansion of its global supply chain network with the acquisition of Bluebird Express, LLC ("Bluebird Express"), a provider of time-sensitive domestic and international transportation services.
- 11/16/2023
|
Cryoport, Inc. (CYRX) Q3 2023 Earnings Call Transcript
- Cryoport, Inc. (NASDAQ:CYRX ) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants Todd Fromer - Investor Relations Jerrell Shelton - Chief Executive Officer Robert Stefanovich - Chief Financial Officer Mark Sawicki - Chief Scientific Officer Thomas Heinzen - Vice President, Corporate Development and Investor Relations Conference Call Participants Paul Knight - KeyBanc David Saxon - Needham John Sourbeer - UBS Jacob Johnson - Stephens Yuan Zhi - B. Riley David Larsen - BTIG Brandon Couillard - Jefferies Richard Baldry - ROTH MKM Puneet Souda - Leerink Partners Operator Good afternoon and welcome to Cryoport Third Quarter 2023 Earnings Conference Call.
- 11/09/2023
|
New Strong Sell Stocks for August 21st
- ALPMY, CYRX and DRCT have been added to the Zacks Rank #5 (Strong Sell) List on August 21, 2023.
- 08/21/2023
|
CryoPort, Inc. (CYRX) Reports Q2 Loss, Tops Revenue Estimates
- CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.17 per share a year ago.
- 08/09/2023
|
Cryoport: Revising To Hold After Major Changes To Forecasts, Sentiment
- Cryoport released preliminary Q2 results, projecting sales to fall behind The Street's estimates. Lower demand for Cryoport's capital equipment and delays in initiating clinical trials are key reasons behind the changes. Management remains optimistic, but the investment facts do not corroborate a buy rating at this point in time in my view.
- 07/14/2023
|
Why Shares of Cryoport are Tumbling Thursday
- Cryoport downgraded annual guidance. The company has seen a slowdown in orders from gene therapy and cell therapy clients.
- 07/13/2023
|
Why Is CryoPort (CYRX) Stock Down 26% Today?
- CryoPort (NASDAQ: CYRX ) stock is falling on Thursday after the cell and gene therapy products company released preliminary results for the second quarter of 2023. The bad news for investors in CYRX stock starts with its expected revenue of $56.5 million to $57.5 million for the quarter.
- 07/13/2023
|
Cryoport shares slide 29% after revenue warning
- Shares of Cryoport Inc. CYRX, +3.58% fell 29% in premarket trading on Thursday after the life-science logistics company issued a revenue warning, noting weaker than expected global demand for capital equipment and clinical trial start delays. Cryoport expects second quarter revenue to be in the range of $56.5 million to $57.5 million, down 11% at the midpoint from the same period a year earlier, the company said in a release late Wednesday.
- 07/13/2023
|
Cryoport: A Strong Player In Cold-Chain Logistics With Solid Growth Prospects
- Cryoport, Inc. is well-positioned to benefit from the growth in the cell and gene therapy industry due to its dominant position in the cold-chain logistics market and potential for substantial revenue growth. The company's global presence and focus on proximity to manufacturing locations, along with strategic acquisitions, have expanded its market presence and boosted demand for its services. I view the stock as a buy and have an end of year price target of $25 on the stock.
- 07/04/2023
|
Cryoport, Inc. (CYRX) Q1 2023 Earnings Call Transcript
- Cryoport, Inc. (NASDAQ:CYRX ) Q1 2023 Earnings Conference Call May 4, 2023 5:00 PM ET Company Participants Todd Fromer - Investor Relations Jerrell Shelton - Chief Executive Officer Robert Stefanovich - Chief Financial Officer Mark Sawicki - Chief Scientific Officer Thomas Heinzen - Vice President, Corporate Development and Investor Relations Conference Call Participants Puneet Souda - SVB Securities Matthew Stanton - Jefferies John Sourbeer - UBS David Larsen - BTIG Paul Knight - KeyBanc Capital David Saxon - Needham & Company Jacob Johnson - Stephens Yuan Zhi - B. Riley Financial Operator Welcome to the Cryoport First Quarter 2023 Earnings Conference Call.
- 05/05/2023
|
CryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue Estimates
- CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.31 per share a year ago.
- 05/04/2023
|
Cryoport, Inc. (CYRX) Q4 2022 Earnings Call Transcript
- Cryoport, Inc. (NASDAQ:CYRX ) Q4 2022 Earnings Conference Call February 23, 2023 5:00 PM ET Company Participants Todd Fromer - Managing Partner-KCSA Jerrell Shelton - Chief Executive Officer Robert Stefanovich - Chief Financial Officer Mark Sawicki - Chief Scientific Officer Conference Call Participants Michael Almisry - SVB Securities Matt Stanton - Jefferies John Sourbeer - UBS David Larsen - BTIG David Saxon - Needham & Company Jacob Johnson - Stephens Yuan Zhi - B. Riley Securities Operator Good afternoon, and welcome to Cryoport's Fourth Quarter and Full Year 2022 Earnings Conference Call.
- 02/23/2023
|
CryoPort, Inc. (CYRX) Reports Q4 Loss, Tops Revenue Estimates
- CryoPort, Inc. (CYRX) delivered earnings and revenue surprises of -14.29% and 4.10%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/23/2023
|
Cryoport: Differentiated Offering In The Life Sciences Value Chain
- Cryoport has been punished over the last 12 months amid a number of downside catalysts. Shares have recently curled up off 52-week lows, asking the question on whether this is an appropriate time for entry.
- 02/08/2023
|
Cryoport: The Golden Stock
- Despite macroeconomic concerns, Cryoport is still generating a 7% revenue growth for the quarter. The new Houston facility that is in collaboration with Takeda would start generating sales as soon as next year.
- 11/16/2022
|
Cryoport, Inc. (CYRX) Q3 2022 Earnings Call Transcript
- Cryoport, Inc. (NASDAQ:CYRX ) Q3 2022 Results Conference Call November 3, 2022 5:00 PM ET Company Participants Todd Fromer - Managing Partner-KCSA Jerrell Shelton - Chief Executive Officer Robert Stefanovich - Chief Financial Officer Dr. Mark Sawicki - Chief Scientific Officer Thomas Heinzen - Vice President, Corporate Development and Investor Relations Conference Call Participants Puneet Souda - SVB Securities John Sourbeer - UBS Brandon Couillard - Jefferies David Larsen - BTIG David Saxon - Needham & Company Yuan Zhi - B. Riley Securities Jacob Johnson - Stephens Operator Good afternoon, and welcome to Cryoport's Third Quarter 2022 Earnings Conference Call.
- 11/05/2022
|
CryoPort, Inc. (CYRX) Reports Q3 Loss, Misses Revenue Estimates
- CryoPort, Inc. (CYRX) delivered earnings and revenue surprises of -15.38% and 13.89%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/03/2022
|
CryoPort, Inc. (CYRX) Stock Jumps 10.5%: Will It Continue to Soar?
- CryoPort, Inc. (CYRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 10/27/2022
|
CryoPort: A Rare Investing Opportunity
- As a small logistic operator servicing other celllular therapy innovators, CryoPort is powered by the prudent merger/acquisition growth approach. Regardless of the bear market, CryoPort has been enjoying huge topline growth from successful acquisitions.
- 09/22/2022
|
Cryoport, Inc. (CYRX) CEO Jerrell Shelton on Q2 2022 Results - Earnings Call Transcript
- Cryoport, Inc. (NASDAQ:CYRX ) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Todd Fromer – Managing Partner-KCSA Jerrell Shelton – Chief Executive Officer Tom Heinzen – Vice President, Corporate Development and Investor Relations Robert Stefanovich – Chief Financial Officer Mark Sawicki – Chief Scientific Officer Conference Call Participants John Sourbeer – UBS Richard Baldry – Roth Capital Yuan Zhi – B. Riley Securities David Saxon – Needham & Co. David Larsen – BTIG Jacob Johnson – Stephens Operator Good afternoon.
- 08/06/2022
|
Cryoport: To Resume Aggressive Growth
- Cryoport is not just any biotech company, as it is banking on the booming logistic businesses for the cell/gene therapy sector. Leveraging the powerful merger and acquisition approach, Cryoport has been enjoying leaping top-line growth year-over-year.
- 05/11/2022
|
Cryoport, Inc.'s (CYRX) CEO Jerrell Shelton on Q1 2022 Earnings Call Transcript
- Cryoport, Inc. (NASDAQ:CYRX ) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Todd Fromer - President, KCSA Strategic Communications Jerrell Shelton - CEO Robert Stefanovich - CFO Mark Sawicki - CSO Conference Call Participants John Sourbeer - UBS Brandon Couillard - Jefferies Michael Jones - SVB Securities Joseph Conway - Needham & Co. Paul Knight - KeyBanc David Larsen - BTIG Yuan Zhi - B. Riley Securities Jacob Johnson - Stephens Operator Thank you for standing by.
- 05/07/2022
|
Cryoport: An Industry Leader Basking In Industry Tailwinds
- Being a logistics service provider for the booming cell/gene therapy sector, Cryoport is enjoying the robust industry tailwind and thereby positioning itself to be an investment bonanza. Various acquisitions like MVE Biological Solutions and CryoPDP are delivering leaping top-line growth for Cryoport.
- 04/15/2022
|
Cryoport: Risky Investment With Upside Potential
- Cryoport: Risky Investment With Upside Potential
- 04/01/2022
|
New Strong Sell Stocks for March 10th
- BSET, CYRX, and DIN have been added to the Zacks Rank #5 (Strong Sell) List on March 10, 2022.
- 03/10/2022
|
CryoPort, Inc. (CYRX) Reports Q4 Loss, Misses Revenue Estimates
- CryoPort, Inc. (CYRX) delivered earnings and revenue surprises of -780% and 2.48%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 02/24/2022
|
Cryoport, Inc.'s (CYRX) CEO Jerrell Shelton on Q4 2021 Results - Earnings Call Transcript
- Cryoport, Inc.'s (CYRX) CEO Jerrell Shelton on Q4 2021 Results - Earnings Call Transcript
- 02/24/2022
|
Here's Why CryoPort, Inc. (CYRX) is Poised for a Turnaround After Losing 22.8% in 4 Weeks
- CryoPort, Inc. (CYRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- 02/23/2022
|
CryoPort (CYRX) Stock: Why The Price Went Down
- The stock price of CryoPort Inc (NASDAQ: CYRX) fell by 2.54% in the most recent trading session. This is why it happened.
- 02/02/2022
|
Cryoport: More Growth Going Into New Year 2022
- The 2021 Biotech Bear market widens the margin of safety for you to build shares in fundamentally robust companies.
- 12/29/2021
|
BioLife: Poised For Growth
- BioLife: Poised For Growth
- 12/22/2021
|
Cryoport's (CYRX) CEO Jerrell Shelton on Q3 2021 Results - Earnings Call Transcript
- Cryoport's (CYRX) CEO Jerrell Shelton on Q3 2021 Results - Earnings Call Transcript
- 11/04/2021
|
Recap: CryoPort Q3 Earnings
- CryoPort (NASDAQ:CYRX) reported its Q3 earnings results on Thursday, November 4, 2021 at 04:05 PM. Here's what investors need to know about the announcement.
- 11/04/2021
|
Cryoport: The Golden Stock
- Cryoport is enjoying extremely aggressive revenue increases. The recent quarter witnessed a near five-fold sales increase year over year. The company is enjoying substantial upsides from the industry tailwind of cell-based therapies innovation.
- 10/08/2021
|
Cryoport: Unfairly Punished, Valuation Update Shows 45% Upside
- Cryoport looks well-positioned to benefit from macroeconomic crosscurrents that are driving value in biological logistics. The company is now supporting 69 Phase 3 clinical trials, evidencing a tide of regulatory momentum yet to be priced in.
- 10/01/2021
|
Cryoport, Mitsubishi Logistics Partner For Temperature-Controlled Supply Chain Solutions
- Cryoport Inc (NASDAQ: CYRX) and Mitsubishi Logistics Corporation (MLC) entered a multi-year strategic business alliance to create an integrated regenerative medicine supply chain partnership in Japan. The financial terms of the deal were not disclosed.
- 08/25/2021
|
Cryoport and Mitsubishi Logistics Corporation Partner to Bring Temperature-Controlled Supply Chain Solutions to Asia-Pacific
- NASHVILLE, Tenn., Aug. 25, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative temperature-controlled supply chain solutions to the life sciences including clinical research, pharmaceutical and cell and gene therapy markets, and Mitsubishi Logistics Corporation ("MLC"), Japan's leading pharma logistics company, today announced a multi-year strategic business alliance to create an integrated regenerative medicine supply chain partnership in Japan.
- 08/25/2021
|
Cryoport, Inc. (CYRX) CEO Jerrell Shelton on Q2 2021 Results - Earnings Call Transcript
- Cryoport, Inc. (CYRX) CEO Jerrell Shelton on Q2 2021 Results - Earnings Call Transcript
- 08/08/2021
|
CryoPort, Inc. (CYRX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
- CryoPort, Inc. (CYRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/29/2021
|
Cryoport (CYRX) Sees Hammer Chart Pattern: Time to Buy?
- Cryoport (CYRX) has been struggling lately, but the selling pressure may be coming to an end soon.
- 07/22/2021
|
What's Next For CryoPort Stock After An 8% Fall In A Week?
- The stock price of CryoPort (NASDAQ: CYRX), a provider of cold chain logistics solutions for biopharmaceutical companies, reached levels of $67 toward the end of June, reflecting a solid 42% gain this year, before a sell-off in the stock, taking it down over 8% to its current level of around $61.
- 07/08/2021
|
Cellenkos® Selects Cryoport to Support On-Demand, Flexible COVID-19 Therapy Shipments to Patients in Need
- NASHVILLE, Tenn., June 22, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or "the Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that Cellenkos ® , Inc., a privately held, clinical-stage biotechnology company, has selected Cryoport to provide a staged, on-demand, logistics solution for COVID-19 therapy shipments for patients in need.
- 06/22/2021
|
Cryoport Further Expands its Asia Pacific Operations with New Global Logistics Center in Singapore
- NASHVILLE, Tenn., May 19, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that its wholly owned operating companies, Cryoport Systems and CRYOPDP, have jointly opened a new Global Logistics Center in Singapore.
- 05/19/2021
|
Cryoport Expands Global Supply Chain Network with Belgium Acquisition
- NASHVILLE, Tenn., May 18, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative temperature-controlled supply chain solutions to the life sciences including clinical research, pharmaceutical and cell and gene therapy markets, today announced the expansion of its global supply chain network with the acquisition of F-Airgate, a provider of innovative temperature-controlled supply chain solutions, headquartered in Brussels, Belgium.
- 05/18/2021
|
Cryoport, Inc. (CYRX) CEO Jerrell Shelton on Q1 2021 Results - Earnings Call Transcript
- Cryoport, Inc. (CYRX) CEO Jerrell Shelton on Q1 2021 Results - Earnings Call Transcript
- 05/04/2021
|
Cryoport to Report First Quarter 2021 Financial Results on May 4, 2021
- NASHVILLE, Tenn., April 27, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the first quarter ended March 31, 2021 on Tuesday, May 4, 2021 after U.S. markets close.
- 04/27/2021
|
Cryoport: Once In A Lifetime Opportunity
- In the past few years, the CAR-T, gene-based, regenerative medicines sector is becoming prominent.
- 04/22/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Cryoport, Inc. (CYRX)
- New York, New York--(Newsfile Corp. - April 8, 2021) - Levi & Korsinsky announces it has commenced an investigation of Cryoport, Inc. (NASDAQ: CYRX) concerning possible breaches of fiduciary duty. To obtain additional information, go to: https://www.zlk.com/compensation2/cryoport-inc-information-request-form or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.
- 04/08/2021
|
Can CryoPort Stock Rebound After A Recent 22% Drop?
- The stock price of CryoPort, a provider of cold chain logistics solutions for biopharmaceutical companies, has seen a large 22% drop over the last five trading days, but we believe the stock, after the recent drop, may trend higher in the near term. The recent drop can largely be attributed to.
- 03/10/2021
|
Cryoport, Inc. (CYRX) CEO Jerrell Shelton on Q4 2020 Results - Earnings Call Transcript
- Cryoport, Inc. (CYRX) CEO Jerrell Shelton on Q4 2020 Results - Earnings Call Transcript
- 03/01/2021
|
CryoPort, Inc. (CYRX) Reports Q4 Loss, Tops Revenue Estimates
- CryoPort, Inc. (CYRX) delivered earnings and revenue surprises of -86.67% and 11.71%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 03/01/2021
|
Cryoport to Report Fourth Quarter and Fiscal Year 2020 Financial Results on March 1, 2021
- NASHVILLE, Tenn., Feb. 25, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the fourth...
- 02/25/2021
|
Cryoport Launches Environmental, Social, and Governance (ESG) Program
- NASHVILLE, Tenn., Feb. 25, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced the launch of its Environmental, Social & Governance (ESG)...
- 02/25/2021
|
Investing Themes for 2021
- 2020 was a year unlike any other in the history of the stock market. Despite the dark clouds hanging over the U.S. and global economy, the S&P 500 Index appreciated 16% in the last year, supported by unprecedented measures taken by both the Federal Reserve and fiscal policymakers to revive business activities.
- 01/25/2021
|
Cryoport Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters to Purchase Additional Shares
- NASHVILLE, Tenn., Jan. 25, 2021 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced the closing of an underwritten public offering of 4,356,059 shares...
- 01/25/2021
|
Cryoport Announces Pricing of Public Offering of Common Stock
- NASHVILLE, Tenn., Jan. 20, 2021 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced the pricing of its underwritten public offering of an aggregate of...
- 01/20/2021
|
Cryoport Announces Proposed Public Offering of Common Stock
- NASHVILLE, Tenn., Jan. 19, 2021 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that it intends to offer $200 million of shares of common stock in...
- 01/19/2021
|
2 Ultra-High-Growth Healthcare Stocks That Are Just Getting Started
- Both stocks are in the early stage of a long-term growth trajectory.
- 12/23/2020
|
Cryoport: Mega Growth Ahead
- With the approval of Yescarta and Kymriah in recent years, you are now seeing unprecedented growth in the CAR-T industry. Logistic providers that support CAR-T and gene therapies are profiting from this fundamental industry tailwind.
- 12/03/2020
|
Logistics of Vaccine Distribution Challenging: Cryoport CEO
- Dec.01 -- Cryoport Inc. looks forward to the opportunity to participate in the distribution of the Covid-19 vaccines and admits the logistics will be challenging, Chief Executive Officer Jerrell Shelton says on "Bloomberg Markets."
- 12/01/2020
|
Cryoport: Insulated Portfolio In Thermoregulatory Logistics Creates Long-Tailed Asset Value
- Cryoport's operating model remains insulated via key differentiators in the thermoregulatory logistics domain, with cloud-based integration along the audit chain. Linking with larger players in providing commercial support gives the ability to generate long-tailed asset returns for value creation.
- 11/23/2020
|
Ultra-Cold Freezer Makers To Profit From Covid-19 Vaccine Rush
- Excited about the Covid-19 vaccines from Pfizer and Moderna? You'll be waiting a long time unless the vaccines can be shipped at 94 degrees below zero.
- 11/21/2020
|
Cryoport, Inc. (CYRX) CEO Jerrell Shelton on Q3 2020 Results - Earnings Call Transcript
- Cryoport, Inc. (CYRX) CEO Jerrell Shelton on Q3 2020 Results - Earnings Call Transcript
- 11/08/2020
|
Cryoport to Report Third Quarter 2020 Financial Results on November 5, 2020
- NASHVILLE, Oct. 29, 2020 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in life sciences solutions, today announced that the Company will report financial results for the third quarter ended September 30, 2020 on Thursday, November 5, 2020...
- 10/29/2020
|
Cryoport: A Levered Refrigerator Manufacturer Trading At A Tech Multiple, $10 Price Target (NASDAQ:CYRX)
- Cryoport is the amalgamation of three separate slow growth businesses wrapped in the auspices of the COVID-19 vaccine effort.
- 10/08/2020
|
How To Predict Sales Growth
- I've found seven factors that correlate highly with future sales growth; this article explains each one.
- 09/08/2020
|
Chart Industries Seeing Stable Industrial Trends, With Long-Term LNG Upside
- Chart has continued to execute well despite a lot of end-market turbulence, industrial gas revenue declined modestly, and LNG revenue growth offset weak natural gas processing demand.
- 09/02/2020
|
Chart Industries: A Look After A Bolt-On Sale
- Chart Industries has announced a divestment, although investors might believe the buying side is the winner here.
- 08/26/2020
|
CRYOPORT, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) | MarketScreener
|
How Much Does Cryoport's (NASDAQ:CYRX) CEO Make?
- Jerrell Shelton has been the CEO of Cryoport, Inc. (NASDAQ:CYRX) since 2012, and this article will examine the...
- 08/11/2020
|
Is Cryoport (NASDAQ:CYRX) Weighed On By Its Debt Load?
- Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
- 08/11/2020
|
Cryoport Reports 2020 Second-Quarter Results
- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in life sciences supply chain solutions, today announced financial results for Second Quarter and six-month period ended June 30, 2020.
- 08/06/2020
|
MEDIPAL HOLDINGS Partners with CRYOPORT to Bring Temperature-Controlled Supply Chain Solutions to the Japanese Market
- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in life sciences supply chain solutions, and MEDIPAL HOLDINGS CORPORATION (7459:JP), ("MEDIPAL") Japan's leading pharma wholesaler and distributor today announced a multi-year strategic business alliance agreement to create an integrated regenerative medicine supply chain solution in Japan.
- 08/04/2020
|
Hub Group Earns IBD Rating Upgrade
- In a welcome move, Hub Group saw its Relative Strength Rating improve from 64 to 78 on Monday. When looking for the best stocks to buy and watch, be sure to pay attention to relative price strength. This proprietary rating identifies technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database.
- 08/03/2020
|
Cryoport to Report Second Quarter 2020 Financial Results on August 6, 2020
- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in life sciences solutions, today announced that the Company will report financial results for the second quarter ended June 30, 2020 on Thursday, August 6, 2020 after U.S. markets close.
- 08/03/2020
|
Cryoport, Inc. (NASDAQ:CYRX) Is Expected To Breakeven
- Cryoport, Inc.'s (NASDAQ:CYRX): Cryoport, Inc. provides temperature-controlled logistics and biostorage services to the...
- 07/10/2020
|
Hedge Funds Are Buying CryoPort, Inc. (CYRX)
- In this article we will check out the progression of hedge fund sentiment towards CryoPort, Inc. (NASDAQ:CYRX) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and 20 […]
- 06/26/2020
|
Agenus and AgenTus to Participate in a Panel Presentation on Cell Therapy at the Raymond James Virtual Human Health Innovation Conference
|
Edited Transcript of CYRX earnings conference call or presentation 7-May-20 9:00pm GMT
- Q1 2020 Cryoport Inc Earnings Call
- 06/08/2020
|
Celyad's Positive Data And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:CYAD)
- Celyad reports positive data for allogenic CAR-T. Sanofi is approved in the EU for Sarclisa in Multiple Myeloma. Abiomed gets IND for its Covid-19 iNKT therapy.
- 06/05/2020
|
China Cold Chain Logistics Industry Report 2020-2026 Featuring Profiles of 22 Operators Including Xianyi Holdings, ZM Logistics, Shandong Gaishi Int'l Logistics Group, Shenyang Nonstaple Food Group - ResearchAndMarkets.com
|
Cryoport, Inc. Prices $100.0 Million Convertible Senior Notes Offering
- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport") today announced the pricing on May 20, 2020 of its offering of $100.0 million in aggregate principal amount of 3.00% convertible senior notes due 2025 (the "notes") in a private offering to investors reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Cryoport also granted the initial purchasers of the notes a 30-day option to purchase up to an additional $15.0 million in principal amount of notes.
- 05/21/2020
|
Cryoport, Inc. Announces Proposed Convertible Senior Notes Offering
- NASHVILLE, Tenn., May 19, 2020 /PRNewswire via COMTEX/ --
NASHVILLE, Tenn., May 19, 2020 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport") today...
- 05/19/2020
|
Cryoport, Inc. Announces Proposed Convertible Senior Notes Offering
- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport") today announced its intention to offer, subject to market and other conditions, $100.0 million in aggregate principal amount of convertible senior notes due 2025 (the "notes") in a private offering to investors reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Cryoport also expects to grant the initial purchasers of the notes a 30-day option to purchase up to an additional $15.0 million in principal amount of notes.
- 05/19/2020
|
U.S. RESEARCH ROUNDUP-Acushnet Holdings, Equity Residential, Fiserv
- Wall Street securities analysts revised their ratings and price targets
on several U.S.-listed companies, including Acushnet Holdings, Equity Residential and Fiserv, on
Monday.
HIGHLIGHTS
* Acushnet Holdings Corp : Stephens raises target price to $27 from $24
* Equity Residential : Evercore ISI raises to in-line from underperform
* Fiserv Inc : Keybanc raises target price to $115 from $108
* GTT Communications Inc : SunTrust Robinson cuts to hold from buy
* UDR Inc : Evercore ISI raises to in-line from underperform
Following is a summary of research actions on U.S. companies reported by Reuters on Monday.
Stock entries are in alphabetical order.
* Abbvie Inc : SVB Leerink raises price target to $122 from $107
* Accelerate Diagnostics Inc : Piper Sandler cuts target price to $14 from $16
* Acushnet Holdings Corp : Compass Point raises TP to $22.25 from $21.50
* Acushnet Holdings Corp : Keybanc raises target price to $31 from $28
* Acushnet Holdings Corp : Stephens raises target price to $27 from $24
* Advance Auto Parts Inc : UBS raises target price to $140 from $135
* AIG : UBS cuts target price to $45 from $49
* Air Lease Corp : Deutsche Bank cuts target price to $36 from $45
* Air Lease Corp : Stephens raises target price to $36 from $30
* Airgain Inc : Northland Capital Markets raises target price to $23
* Alarm.Com Holdings Inc : Credit Suisse cuts target price to $62 from $64
* Albemarle Corp : RBC raises target price to $66 from $64
* Albemarle Corp : SunTrust Robinson cuts target price to $65 from $90
* Allegiant Travel Co : Evercore ISI cuts target price to $95 from $100
* Allscripts Healthcare Solutions : Canaccord Genuity cuts TP to $11 from $13
* Amdocs Ltd : Citigroup cuts price target to $76 from $83
* Amedisys Inc : Raymond James cuts price target to $210 from $225
* Amedisys Inc : UBS cuts target price to $190 from $208
* American Axle & Manufacturing Holdings : Citigroup raises TP to $7.5 from $6
* American Axle & Manufacturing Holdings : RBC raises target price to $7 from $5
* American Homes 4 Rent : Evercore ISI raises target price to $27 from $25
* Ameriprise Financial Inc : RBC raises target price to $155 from $145
* Amerisourcebergen Corp : Deutsche Bank raises target price to $98 from $93
* Amphastar Pharmaceuticals Inc : BMO raises price target to $21 from $20
* Angi Homeservices Inc : Citigroup raises price target to $10 from $6.5
* Aon Plc : Citigroup cuts price target to $230 from $240
* Aon Plc : KBW raises target price to $192 from $184
* Aon Plc : UBS cuts target price to $197 from $202
* Apache Corp : CFRA cuts to sell from hold; raises price target to $9
* Apache Corp : MKM Partners cuts target price by $1 to $19
* Aptiv Plc : Benchmark cuts price target to $87 from $90
* Arch Capital Group Ltd : UBS cuts target price to $39 from $43
* Atara Biotherapeutics Inc : Jefferies cuts target price to $11 from $13
* Athene Holding Ltd : BMO cuts price target to $60 from $63
* Atricure Inc : BTIG raises target price to $56 from $45
* Atricure Inc : Needham raises target price to $63 from $49
* Atricure Inc : Oppenheimer raises price target to $52 from $45
* Atricure Inc : SVB Leerink raises price target to $55 from $50
* Autonation Inc : CFRA cuts price target by $10 to $50
* Avalonbay Communities Inc : Evercore ISI cuts target price to $181 from $189
* Avista Corp : Guggenheim cuts target price to $38 from $39
* Bain Capital Specialty Finance : Citigroup raises price target to $10 from $7.5
* Ball Corp : Citigroup cuts price target to $86 from $89
* Ball Corp : Northland Capital Markets cuts target price to $80
* Baudax Bio Inc : Oppenheimer cuts price target to $14 from $16
* Bellring Brands Inc : Stifel cuts target price to $23 from $25
* BJ's Restaurants Inc : Deutsche Bank raises target price to $27 from $26
* Bloomin' Brands Inc : BMO raises price target to $10 from $9
* Bloomin' Brands Inc : Deutsche Bank raises target price to $15 from $14
* Bloomin' Brands Inc : Guggenheim raises target price to $15 from $11
* Bloomin' Brands Inc : Raymond James cuts target price to $14 from $15
* BP Midstream Partners LP : Mizuho raises target price to $14 from $13
* Broadridge Financial Solutions : Piper Sandler cuts TP to $120 from $124
* Broadridge Financial Solutions : Rosenblatt Securities ups TP to $115 from $101
* Brookfield Infrastructure Partners LP : BMO raises price target to $46 from $45
* Brookfield Infrastructure Partners LP : Scotiabank cuts Tp to $50 from $51
* Brookfield Property Partners LP : Canaccord Genuity cuts TP to $12 from $13
* Brookfield Property Partners LP : CIBC cuts target price to $18 from $20.50
* Brookfield Property Partners LP : RBC cuts target price to $18 from $22
* Bruker Corp : BTIG cuts price target to $50 from $57
* Cabot Oil & Gas Corp : Tudor Pickering Holt cuts to hold from buy
* Calithera Biosciences Inc : Citigroup raises price target to $10 from $7
* Callaway Golf Co : >: Compass Point cuts target price to $17.50 from $20
* Callaway Golf Co : Compass Point cuts target price to $17.50 from $20
* Camden Property Trust : Evercore ISI cuts target price to $98 from $102
* Camden Property Trust : Stifel raises target price to $96 from $91
* Cardtronics Plc : D.A. Davidson cuts target price to $34 from $40
* Cardtronics Plc : SunTrust Robinson raises target price to $29 from $23
* Cargurus Inc : RBC raises target price to $25 from $22
* Carnival : HSBC raises to buy from hold; cuts target price to $15.9 from $45.3
* Carrier Global Corp : Citigroup raises price target to $20 from $17
* Carvana Co : Oppenheimer raises price target to $127 from $95
* Carvana Co : Oppenheimer raises target price to $127 from $95
* Casella Waste Systems Inc : Jefferies raises target price to $56 from $52
* Casella Waste Systems Inc : Raymond James raises target price to $56 from $49
* Casella Waste Systems Inc : Stifel raises target price to $47 from $45
* Cellectis : Citigroup cuts price target to $15 from $16
* Centurylink Inc : SunTrust Robinson cuts target price to $9 from $10
* Ceridian Hcm Holding Inc : Jefferies raises target price to $65 from $60
* Chevron Corp : Independent Research raises target price to $98 from $90; hold
* CNX Resources Corp : Tudor Pickering Holt cuts to hold from buy
* Cognizant Technology Solutions : Evercore ISI cuts target price to $53 from $55
* Cognizant Technology Solutions Corp : HSBC cuts target price to $56 from $70
* Coherus Biosciences Inc : Citigroup cuts price target to $30 from $31
* Conagra Brands Inc : SunTrust Robinson cuts to hold from buy
* Consolidated Edison Inc : Evercore ISI cuts target price to $85 from $86
* Continental Resources : TD Securities raises target price to $14.50 from $13.50
* Cooper Tire & Rubber Co : JP Morgan cuts target price to $29 from $30
* Corporate Office Properties Trust : SunTrust Robinson raises TP to $28 from $26
* Corteva Inc : RBC raises target price to $31 from $27
* Covanta Holding : Stifel raises to hold from sell; raises TP to $9.50 from $6.50
* Crocs Inc : Piper Sandler raises target price to $28 from $24
* Cross Country Healthcare Inc : BMO cuts price target to $8 from $11
* Cryoport Inc : Stephens raises target price to $23 from $21
* CVR Energy Inc : Credit Suisse raises target price to $19 from $16
* Cytomx Therapeutics Inc : Wedbush raises target price to $16 from $11
* Danaher Corp : Evercore ISI raises target price to $175 from $150
* Danaher Corp : RBC raises target price to $173 from $159
* Datadog Inc : RBC raises target price to $50 from $43
* Dentsply Sirona : Barrington Research cuts to market perform from outperform
* Dentsply Sirona Inc : UBS cuts target price to $44 from $59
* Dicerna Pharmaceuticals : SunTrust Robinson raises target price to $33 from $28
* Diebold Nixdorf Inc : JP Morgan raises target price to $7 from $6
* Diebold Nixdorf Inc : JP Morgan raises to neutral from underweight
* Discovery Inc : Rosenblatt Securities cuts price target to $24 from $27
* Dish Network Corp : RBC cuts target price to $32 from $39
* Domtar : D.A. Davidson cuts to neutral from buy; cuts TP to $26 from $44
* Domtar Corp : Scotiabank cuts target price to $29 from $30
* Domtar Corp : TD Securities raises target price to $26 from $22
* E. W. Scripps Co : Benchmark cuts target price to $15 from $24
* E. W. Scripps Co : Guggenheim raises target price to $8 from $6.50
* Edison Intl.
- 05/11/2020
|
Cryoport, Inc. (NASDAQ:CYRX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
- It's been a pretty great week for Cryoport, Inc. (NASDAQ:CYRX) shareholders, with its shares surging 15% to US$20.74...
- 05/10/2020
|
Cryoport, Inc. (CYRX) CEO Jerrell Shelton on Q1 2020 Results - Earnings Call Transcript
- Cryoport, Inc. (NASDAQ:CYRX) Q1 2020 Earnings Conference Call May 7, 2020 05:00 PM ET Company Participants Todd Fromer - Managing Partner, KCSA Jerrell Shelton
- 05/10/2020
|
Cryoport (CYRX) Q1 2020 Earnings Call Transcript
- Before we begin today, I would like to remind everyone that this conference call contains certain forward-looking statements. All statements that address our operating performance, events or developments that we expect or anticipate occurring in the future are forward-looking statements.
- 05/10/2020
|
U.S. RESEARCH ROUNDUP-Becton Dickinson, Epam Systems, PayPal Holdings
- Wall Street securities analysts on Friday revised their ratings and price targets on several
U.S.-listed companies, including Becton Dickinson, Epam Systems and PayPal Holdings.
HIGHLIGHTS
* Becton Dickinson and Co : Citigroup raises price target to $260 from $234
* Carrols Restaurant Group Inc : Craig-Hallum raises to buy from hold; raises target price to $5 from $3.75
* Computer Programs and Systems Inc : Cantor Fitzgerald raises to overweight from neutral
* Epam Systems Inc : Citigroup raises price target to $265 from $245
* PayPal Holdings Inc : Citigroup raises price target to $145 from $131
Following is a summary of research actions on U.S. companies reported by Reuters on Friday. Stock entries are in alphabetical
order.
* Aaron's Inc : Keybanc cuts target price to $55 from $66
* Aaron's Inc : Raymond James cuts target price to $50 from $60
* Aaron's Inc : Stephens raises target price to $45 from $26
* Abeona Therapeutics Inc : RBC cuts target price to $7 from $11
* Acceleron pharma Inc : Credit Suisse raises target price to $123 from $99
* ACI Worldwide Inc : Canaccord Genuity cuts target price to $35 from $44
* Acushnet Holdings Corp : Jefferies raises target price to $25 from $24
* Acushnet Holdings Corp : JP Morgan raises target price to $30 from $27
* Adtran Inc : Cowen and Company raises price target to $13 from $9
* Aeglea Bio Therapeutics Inc : Needham cuts price target to $11 from $14
* Aerie Pharmaceuticals Inc : Citigroup cuts price target to $38 from $39
* Agco Corp : Citigroup cuts price target to $55 from $57
* AIG : KBW raises target price to $36 from $35
* Alaska Air Group Inc : Credit Suisse cuts target price to $51 from $82
* Allison Transmission Holdings Inc : Citigroup raises price target to $39 from $38
* Allscripts Healthcare Solutions : Cantor Fitzgerald cuts PT to $6 from $8
* Alteryx Inc : Guggenheim cuts target price to $130 from $160
* American Airlines : Credit Suisse cuts target price to $4 from $26
* Ameriprise Financial Inc : Credit Suisse raises target price to $165 from $153
* Ameriprise Financial Inc : Piper Sandler raises target price to $150 from $130
* Amerisourcebergen Corp : Baird raises target price to $115 from $109
* Amerisourcebergen Corp : Mizuho raises target price to $90 from $85
* Amtech Systems Inc : Cowen and Company raises target price to $7.50 from $7
* Angi Homeservices Inc : Needham raises target price to $11 from $8
* Ani Pharmaceuticals Inc : Guggenheim cuts target price to $48 from $58
* Ansys Inc : RBC raises target price to $260 from $230
* Anthem Inc : Bernstein raises target price to $357 from $342
* Appian Corp : Cowen and Company raises price target to $44 from $39
* Applied Optoelectronics Inc : D.A. Davidson raises target price to $12 from $10
* Applied Optoelectronics Inc : Piper Sandler raises target price to $10 from $7.50
* Aptiv Plc : Citigroup raises price target to $84 from $67
* ArcelorMittal SA : Keybanc raises target price to $15 from $13
* Arcturus Therapeutics Holdings Inc : Baird raises target price to $44 from $26
* Arcturus Therapeutics Holdings Inc : Guggenheim raises target price to $51 from $41
* Ares Capital Corp : Citigroup raises price target to $15 from $13
* Athersys Inc : Needham cuts price target to $5 from $6
* Atlas Air Worldwide Holdings Inc : Cowen and Company raises PT to $44 from $40
* Avalara Inc : Canaccord Genuity raises target price to $115 from $105
* Avalara Inc : JP Morgan raises target price to $120 from $104
* Avalara Inc : Mizuho raises price target to $120 from $85
* Avalara Inc : Piper Sandler raises target price to $113 from $90
* Avalonbay Communities Inc : Stifel raises target price to $176 from $171
* Avrobio Inc : Guggenheim raises target price to $50 from $49
* Axalta Coating Systems Ltd : RBC raises target price to $21 from $20
* Bausch Health Companies Inc : Piper Sandler cuts target price to $32 from $34
* Beacon Roofing Supply Inc : SunTrust Robinson raises target price to $26 from $24
* Beacon Roofing Supply Inc : Wedbush raises target price to $23 from $16
* Becton Dickinson and Co : Citigroup raises price target to $260 from $234
* Becton Dickinson and Co : Evercore ISI raises target price to $270 from $255
* Beyond Meat Inc : Berenberg raises price target to $125 from $115
* Bill.Com Holdings Inc : Canaccord Genuity raises target price to $65 from $50
* Bill.Com Holdings Inc : Jefferies raises target price to $70 from $45
* Bill.Com Holdings Inc : Keybanc raises target price to $76 from $60
* Bill.Com Holdings Inc : Needham raises target price to $90 from $55
* Biomarin Pharmaceutical Inc : Canaccord Genuity raises PT to $119 from $108
* BJ's Restaurants Inc : Wedbush cuts target price to $32 from $39
* Booking Holdings Inc : Credit Suisse raises target price to $1,810 from $1,790
* Booking Holdings Inc : Jefferies cuts target price to $1300 from $1350
* Booking Holdings Inc : Mizuho cuts price target to $1700 from $1720
* Booking Holdings Inc : RBC raises target price to $1,550 from $1,535
* Booking Holdings Inc : RBC raises target price to $1550 from $1535
* BorgWarner Inc : Citigroup raises price target to $30 from $23
* BorgWarner Inc : Credit Suisse raises target price to $33 from $31
* Bottomline Technologies (De) Inc : Citigroup raises price target to $46 from $43
* Bright Horizons Family Solutions Inc : Citigroup raises PT to $122 from $80
* Brightsphere Investment Group Inc : Evercore ISI raises target to $9 from $6
* Brightsphere Investment Group Inc : KBW raises target price to $9.50 from $7.25
* Brightview Holdings Inc : Credit Suisse cuts target price to $14 from $18
* Brightview Holdings Inc : Jefferies raises target price to $14 from $12
* Cabot Microelectronics Corp : Citigroup cuts price target to $140 from $175
* Cactus Inc : zephirin Group raises price objective to $12 from $8
* Calithera Biosciences Inc : Jefferies raises target price to $9 from $6
* Calyxt Inc : BMO cuts price target to $7 from $13
* Calyxt Inc : BMO cuts to market perform from outperform
* Camping World Holdings Inc : Credit Suisse raises target price to $12 from $11
* Camping World Holdings Inc : JP Morgan raises price target to $11 from $10
* Capstar Financial Holdings Inc : KBW raises target price to $11 from $10.50
* Cargurus Inc : BTIG raises target price to $26 from $23
* Carrols Restaurant Group Inc : Craig-Hallum raises to buy from hold; raises target price to $5 from $3.75
* Castlight Health Inc : Cantor Fitzgerald cuts target price to $1 from $2
* Catasys Inc : Canaccord Genuity raises target price to $36 from $35
* CBRE Group Inc : Evercore ISI cuts target price to $48 from $50
* CBRE Group Inc : KBW cuts target price to $51 from $52
* Centerpoint Energy Inc : Guggenheim raises target price to $26 from $25
* Centerpoint Energy Inc : Keybanc raises target price to $16 from $12
* Centurylink Inc : RBC cuts target price to $10 from $14
* CF Industries Holdings Inc : Citigroup cuts price target to $29 from $31
* CF Industries Holdings Inc : Scotiabank raises target price to $32 from $31
* ChannelAdvisor Corp : Needham raises price target to $14 from $11
* Charles River Laboratories International : Credit Suisse cuts PT to $159 from $162
* Charles River Laboratories International : Evercore ISI ups PT to $176 from $154
* Charles River Laboratories International : Jefferies raises PT to $161 from $139
* Charles River Laboratories International Inc : Citigroup raises price target to $190 from $165
* Chart Industries Inc : zephirin Group raises price objective to $25 from $17
* Charter Communications Inc : Benchmark raises price target to $600 from $523
* Chemours Co : Citigroup raises price target to $13 from $8
* Cimarex Energy Co : MKM Partners raises target price to $34 from $31
* City Holding Co : Stephens cuts target price to $63 from $64.
- 05/08/2020
|
/C O R R E C T I O N -- Cryoport, Inc./
- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport"), a global leader in life sciences solutions, today announced financial results for the three-month period ended March 31, 2020.
- 05/07/2020
|
Cryoport to Report First Quarter 2020 Financial Results on May 7, 2020
- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport" or the "Company"), a global leader in life sciences solutions, today announced that the Company will report financial results for the first quarter ended March 31, 2020 on Thursday, May 7, 2020 after U.S. markets close.
- 04/30/2020
|
Columbus Circle Investors Lowers Position in CryoPort Inc (NASDAQ:CYRX)
- Columbus Circle Investors lessened its position in CryoPort Inc (NASDAQ:CYRX) by 11.9% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 318,454 shares of the consumer goods maker’s stock after selling 43,153 shares during the quarter. Columbus Circle Investors owned approximately 0.85% […]
- 04/30/2020
|
We're Excited To See How Cryoport (NASDAQ:CYRX) Uses Its Cash Hoard To Grow
- There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
- 03/31/2020
|
Edited Transcript of CYRX earnings conference call or presentation 5-Mar-20 10:00pm GMT
- Q4 2019 Cryoport Inc Earnings Call
- 03/26/2020
|
Analysts Are Bullish on Top Consumer Goods Stocks: Marvell (MRVL), CryoPort (CYRX)
- There's a lot to be optimistic about in the Consumer Goods sector as 2 analysts just weighed in on Marvell (MRVL) and CryoPort (CYRX) with bullish
- 03/06/2020
|
Analysts Are Bullish on Top Consumer Goods Stocks: Marvell (MRVL), CryoPort (CYRX)
- There’s a lot to be optimistic about in the Consumer Goods sector as 2 analysts just weighed in on Marvell
- 03/06/2020
|
Cryoport Reports Record Revenue for Fiscal Year 2019
- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport"), a global leader in life sciences solutions, today announced financial results for the three and twelve-month periods ended December 31, 2019.
- 03/05/2020
|
CryoPort, Inc. to Host Earnings Call
- NEW YORK, NY / ACCESSWIRE / March 5, 2020 / CryoPort, Inc. (CYRX) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 5, 2020 at 5:00 PM Eastern Time. ...
- 03/05/2020
|
Rock star Growth Puts Cryoport (NASDAQ:CYRX) In A Position To Use Debt
- Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
- 03/02/2020
|
Cryoport to Report Fourth Quarter and Fiscal Year 2019 Financial Results on March 5, 2020
- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport" or the "Company"), a global leader in life sciences solutions, today announced that the Company will report financial results for the fourth quarter and fiscal year ended December 31, 2019 on Thursday, March 5, 2020 after U.S. markets close.
- 02/27/2020
|
Cryoport and Inception Fertility Enter Into Agreement
- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today announced a multi-year agreement with Inception Fertility, LLC ("Inception Fertility"), a Houston-based company which operates The Prelude Network, the largest and fastest growing network of fertility centers in the United States and MyEggBank, one of the largest frozen donor egg banks in North America. Under the terms of this partnership, The Prelude Network and MyEggBank will utilize Cryoport's temperature-controlled supply chain solutions to deliver a superior patient experience across its entire clinical network, which will provide significant risk mitigation for its clients.
- 02/26/2020
|
Exclusive: Publicly traded California company moves HQ to Brentwood
- The temperature-controlled logistics company is the latest in a string of California companies to move their headquarters to Music City.
- 02/03/2020
|
Should You Worry About Cryoport, Inc.'s (NASDAQ:CYRX) CEO Salary Level?
- Jerrell Shelton has been the CEO of Cryoport, Inc. (NASDAQ:CYRX) since 2012. This analysis aims first to contrast CEO...
- 01/24/2020
|
Analysts: The 5 Top Stocks You’ll Want to Own In 2020
- We are still in the earliest days of the new decade, one sure to bring with it a plethora of changes. Some we can already foresee happening, while others remain unknowable to us.One certainty which will forever remain, though, involves investors’ hard-earned cash. Namely, everybody will always want to know where the best opportunities for ample returns lay.So, how to find out, then? As is de rigueur in the investment fraternity, the new year comes along with recommendation lists. Joining the fray is California based investment firm, Roth Capital. The company is adept at unearthing untapped potential with its primary focus on small-caps.We decided to get the scoop on 5 companies the investment firm thinks stand to make headway in 2020. All choices, according to the analysts, have room for solid upside, and, additionally, all currently hold a Strong Buy consensus rating from the Street. Here’s the lowdown.PowerFleet Inc (PWFL)Let’s start with one of Roth’s choices in the technology sector. Formerly known as I.D. Systems, PowerFleet is a pioneer in the use of radio frequency identification (RFID) technology for industrial asset tracking and management. With its patented systems for managing high value assets, the company serves big industry names such as Ford and Avis, as well as the U.S. Postal Service.The company’s latest earnings report achieved record quarterly revenue of $16.9 million, representing a year-over-year increase of 26%. The quarter also saw the company sign a number of deals with major players such as Knight-Swift, The Scotts Miracle-Gro Company, B.A.H. Express and Jungheinrich.In October PowerFleet completed the acquisition of Israeli based Pointer Telocation, a leading provider of telematics and mobile IoT solutions, for approximately $140 million. Roth’s William Gibson views “the combination as transformational, positioning the company for additional and larger orders.”“Our 2020 estimate is in line with guidance, earnings of $7.6 million or $0.26 per share on revenue of $153 million. Cross-selling opportunities are well underway and should result in meaningful upside to guidance,” the analyst said.Gibson, therefore, reiterated a Buy rating on PWFL, and kept his price target of $10.30 intact. Should the objective play out, gains of 46% could be heading investors’ way over the next 12 months. (To watch Gibson’s track record, click here)2 other analysts are currently tracking the asset tracker, with both recommending the stock a Buy. PowerFleet’s Strong Buy consensus rating is accompanied by an average price target of $10.83 and represents possible upside of 54%. (See PowerFleet stock analysis on TipRanks)Forty Seven Inc (FTSV)Moving on to the healthcare sector, we encounter Forty Seven Inc. The biotech is engaged in finding novel and more compassionate ways to fight cancer. FTSV has been turning heads on the Street recently, as December saw a tripling of its share price.The reason? Last month, Forty Seven announced promising updated clinical data from its ongoing phase Ib trial evaluating Magrolimab in combination with Azacitidine for the treatment of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).The combination of Magrolimab and Azacitidine proved to be highly active and well-tolerated in patients with MDS and AML. Magrolimab is a humanized monoclonal antibody targeting CD47, which is a “don’t eat me” signal to macrophages and is expressed on all cells.After such a mercurial run up, what might move the stock even further?Roth’s Anthony Butler thinks It could be “inferences of magrolimab’s utility in solid tumors.” The 4-star analyst further expounded, “While we do not know the data, an early Phase Ib trial of magrolimab plus cetuximab in colorectal cancer will be presented at the Gastrointestinal Cancers Symposium (ASCO-GI) January 23-25 in San Francisco and as well as magrolimab plus avelumab in ovarian cancer at ASCO-SITC Clinical Immuno-Oncology Symposium February 6-8 in Orlando. The trials could possibly provide an early read on the utility of magrolimab in solid tumors. Any positive data most likely will increase the value of the stock.”Butler confirmed his bullish take on Forty Seven by reiterating a Buy rating on the cancer fighter. The analyst’s price target is $55 and implies upside potential of 56%. (To watch Butler’s track record, click here)It looks like the rest of the Street unanimously agrees with the Roth analyst. A Strong Buy consensus rating is formed of solely Buy ratings – 9, in fact. 13% upside could be in the cards should the average price target of $41.75 be achieved over the coming 12 months. (See Forty Seven stock analysis on TipRanks)NV5 Holdings (NVEE)NV5 Holdings suffered badly in the bull market of 2019, losing almost 17% of its value over the year. A series of disappointing earnings reports hampered the stock’s growth potential. The infrastructure-focused engineering and consulting company has started the new decade well, though, and is so far up by over 10% year-to-date.NV5 have been busy on the acquisition front; In December, the company completed the purchase of Geospatial Holdings (QSI), the US's largest independent geospatial analytics firm for approximately $318 million. The acquisition was the company’s 7th in 2019 alone.Roth’s Jeff Martin thinks a turnaround is due and foresees the trend extending further into 2020. The 5-star analyst said, “We chose NVEE as the top pick for Business Services in anticipation of the improved margin profile of the business in 2020. We model a 420bp improvement in adjusted EBITDA margin (on net revenue) to 21.2%, aided by the 24% margin from the QSI acquisition. QSI also brings organic growth potential and continued strength in NVEE’s Energy group aid in the return to organic growth in 2020.”Martin, accordingly, reiterated a Buy rating on NV5, along with a price target of $91. This implies upside potential of a not inconsiderable 63.5%. (To watch Martin’s track record, click here)Overall, those keeping an eye on NVEE stock remain with the bulls. NV5’s 3 Buy ratings coalesce into a Strong Buy consensus rating and come accompanied with an average price target of $87.33. The figure indicates upside potential of over 60% upside. (See NV5 stock analysis on TipRanks)Aspen Group Inc (ASPU)Combining tech with education, Aspen group has two for-profit universities under its holdings umbrella, Aspen University and United States University. The company provides online degrees along with on-campus studies.ASPU’s innovative monthly payment plan allows students to pursue degrees without the burden of student loans, while the university’s option to pay in monthly increments provides the ability to pay for education in significantly lower amounts. Aspen has been posting impressive growth figures in its latest earnings report, exhibiting 49% year-over-year growth, while also reporting record revenue of $12.1 million.Roth’s Darren Aftahi anticipates “continued topline growth (~36% y/y NTM) to be driven by further expansion of ASPU’s two higher growth and profit segments, USU and Pre-Licensure (PL).” The 5-star analyst further added, “We expect variable enrollment costs to be kept stable as ASPU should continue to benefit from its industry differentiating EdTech enrollment CRM (and with it double-digit conversion rates), suggesting continued leverage in marketing costs y/y, while maintaining double-digit enrollment growth (with upside in 2H20 from the launch of 2 additional PL campuses). Shares remain attractive trading at <2.5x FY21 revenue on ~30% y/y growth and runway for incremental profitability in the NTM.”Unsurprisingly, then, Aftahi kept his Buy rating on ASPU, along with his price target of $11. The figure indicates potential upside of 40%. (To watch Aftahi’s track record, click here)When put together, Aspen’s 4 Buy recommendations from the Street add up to a Strong Buy consensus rating. An average price target of $10.75 indicates possible gains of 36%. (See Aspen stock analysis on TipRanks)CryoPort Inc (CYRX)With Roth’s final pick we head back to the tech sector. Cryoport provide logistic solutions for the life sciences industry. Specifically, the company deals in the global transportation of temperature-sensitive materials and serves biopharmaceutical, IVF and surrogacy and animal health organizations around the world.The company is growing rapidly and making its way towards profitability. In 3Q19 revenues were up by 81% year-over-year with reported record revenue of $9.6 million. The company is expected to start turning a profit in 2021.After CYRX’s share price rose by over 150% in 2019’s first eight months, the final months of the year saw it experience a pullback. Roth’s Richard Baldry, though, sees the retracement as an opportunity. The 5-star analyst picks Cryoport’s as his “top Software sector pick for 2020.” Baldry said, “As CYRX’s clinical trial customer base increases and commercial therapies supported expand, we expect rapid growth and record revenue and earnings results in 2020, at odds with the roughly 40% pullback in its shares from recent highs.”To this end, Baldry reiterated a Buy on Cryoport, alongside a price target of $30. Should the target be met, investors stand to take home an increase in the shape of 75%. (To watch Baldry’s track record, click here)CYRX’s fans on the Street are few, yet vocal. Of the remaining 2 analysts chiming in with an opinion on the logistics company, both consider Cryoport a Buy. Therefore, Cryoport receives Strong Buy status. With an average price target of $23.67, the upside potential comes in at 38%. (See Cryoport price targets and analyst ratings on TipRanks)
- 01/10/2020
|
Cryoport Announces Preliminary Fourth Quarter and Full Year 2019 Revenue
- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today announced preliminary revenue for the twelve and three-month periods ended December 31, 2019, based upon preliminary unaudited financial information.
- 01/09/2020
|
Is CryoPort, Inc. (CYRX) A Good Stock To Buy?
- Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
- 12/15/2019
|
Cryoport, Inc. (NASDAQ:CYRX): When Will It Breakeven?
- Cryoport, Inc.'s (NASDAQ:CYRX): Cryoport, Inc. provides temperature controlled logistics solutions to the life sciences...
- 12/10/2019
|
3 ‘Perfect 10’ Stocks With Plenty of Upside Ahead
- 10 is a majestic number. Used to bestow a quality of unmatched excellence, be it as a score in a gymnastics routine, or as a number on the back of a sportsman/woman’s shirt, indicating leadership and guru-like status.TipRanks makes good use of the aspirational number too. The Smart Score tool combines 8 key metrics that can indicate a stock’s long-term growth potential. The data is analyzed, and the stock is given a score accordingly. The highest score, naturally, is a “Perfect 10”.Setting out on our quest for perfection, with the Smart Score’s assistance, we homed in on 3 Perfect 10 Stocks with plenty of room for growth ahead. Let’s take a look.Yeti Holdings (YETI)Unicorn brands are a rare sight; hence they’re called - you guessed it - unicorn brands. The title refers to a privately held company that reaches a value of $1 billion. One such brand making quite a splash since going public is Yeti Holdings.The outdoor product manufacturer held its IPO in October 2018 and has mostly been on a cool upward trend ever since. It has made excellent progress in building its brand identity, seducing lovers of the outdoor lifestyle with its varied line of products. As a result, it now boasts 1.3 million followers on Instagram. Following previous strong quarters, 3Q continued the trend. Sales came in at $229M beating the $222M estimate, alongside increasing sales growth. Yeti delivered on EPS too - at $0.30 it beat the Street’s estimate of $0.26.Looking ahead, Jefferies’ 4-star analyst Randal Konik thinks the growth is set to continue, noting, “YETI is a brand that consumers (Pros/ Joes) love & also see as a gifting destination.” He adds, “We see significant opportunity for YETI to expand its TAM as it broadens its exposure to non-heritage markets in the US and international over the long-term. With continuous innovation in new and existing product categories, and a quickly growing margin-enhancing DTC channel, we believe top-line and margin opportunities are significant.” On the back of his analysis, Konik reiterated a Buy rating on Yeti, with a price target of $47.00, providing potential upside of almost 60%. (To watch Konik’s track record, click here)Another analyst singing YETI’s praises is Piper Jaffrey’s Peter Keith, who said, “Business momentum remains strong and we see upside to implied Q4 guidance. Importantly, we believe YETI is demonstrating longer-term growth potential, considering success with new product launches, steady/consistent gross margin expansion, intriguing store expansion opportunity both w/ Wholesale and DTC, and engaging marketing.” Like Konik, Keith reiterated a Buy on the stock, with a price target of $39.00. (To watch Keith’s track record, click here)The analysts’ positive sentiment is shared by the Street, as Yeti currently ranks as a Strong Buy. The cooler manufacturer has a consensus of 7 Buys and 1 Hold with an average price target of $40.50. This implies handsome potential upside of over 37% from its current price of $29.41. (See Yeti stock analysis on TipRanks)CryoPort (CYRX)With a motto of “Science. Logistics. Certainty.” CryoPort, which provides cold chain logistics solutions to the life sciences industry, presents itself boldly.In layman’s terms, it is a frozen shipping container company moving biological specimens around the world in sub-zero temperatures. Its clients include biopharmaceutical, IVF and surrogacy as well as animal health organizations across the globe.The company recently posted strong 3Q19 results, with revenue up 81% year-over-year, and positive adj. EBITDA for the second consecutive quarter. Among the highlights in the report were increased market share in the regenerative medicine clinical trial sector and a strategic partnership with Lonza. Lonza provides product development services to the pharmaceutical and biologic industries and is considered one of the largest players in the field. Needham’s 4-star analyst Stephen Unger thinks the partnership is good news for CryoPort, noting, “The goal of the partnership is to provide customers developing cell and gene therapies with a fully integrated solution for outsourced manufacturing and cold-chain logistics, which we see increasing customer visibility of CYRX's best-in-class logistics solutions earlier in the therapy development process.” Following the quarterly report and positive developments, Unger maintained his Buy rating on CYRX. His price target is $24.00. (To watch Unger’s track record, click here)B.Riley FBR’s Andrew D'Silva is also impressed with the partnership. The analyst said, “We believe Lonza has positioned itself as one of the cell and gene therapy industry's leading contract development and manufacturing organizations (CDMOs). As a result, we believe CYRX being selected as Lonza's preferred partner is another substantial validation for the company and should help further increase CYRX's logistics volumes.”To this end, D’Silva reiterated his Buy rating on CYRX stock, along with a price target of $26.00, providing potential upside of 70%. (To watch D’Silva’s track record, click here) Not many analysts have presently weighed in on the small cap’s potential for the year ahead. With a consensus of 2 Buys, CYRX currently ranks as a Moderate Buy. That being said, the average price target is $25.00, implying nice upside of almost 64% from its current price of $15.56. (See Cryoport stock analysis on TipRanks)Sonos (SONO)Speakers act louder than words, so the phrase goes. Well, not quite, but it does lead us nicely to our final choice.Consumer electronics company Sonos is mostly known for its smart speakers. Apart from the excellent sound quality, Sonos’ Sonoset system creates a custom Wi-Fi network, eliminating the need for old fashioned wires and allowing for music to be played simultaneously in different rooms. This is great for household systems, and earlier this year Sonos partnered with furniture giant Ikea on a new line of products, an alliance RBC Capital’s Robert Muller thinks has the potential to drive new customer adoption. The analyst said, “We believe the true value of Sonos lies in the family ecosystem whereby additional speakers complement one another. Once exposed to Sonos, we expect new customers to quickly envision the benefits of additional speakers throughout their homes. If SONO is able to expand the number of homes it's in (currently in ~8MM worldwide with nearly 4MM in the US), we should see a wave of secondary purchases.”Emphasizing this thesis, Muller says almost 4 out of 10 new purchases are from existing Sonos customers. Furthermore, the analyst also views SONO as a potential acquisition target for one of the tech giants, adding, “We do not believe current valuation adequately captures acquisition potential, expansion opportunities, or current baseline growth”. Following his analysis, Muller initiated coverage, along with a price target of $18.00. (To watch Muller’s track record, click here). A consensus rating of 3 Buys and 1 Hold means the Street is ready to turn the volume up on Sonos, rating the speaker manufacturer as a Strong Buy. The average price target is $18.25, providing upside of 24% from its current price of $14.70. (See Sonos stock analysis on TipRanks)
- 11/19/2019
|
